Nachrichten zur GSK PLC Aktie

GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute

GSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and…

GSK Set for $500 Million Payment From mRNA Lawsuit Settlement

CureVac NV has settled a long-running patent dispute over mRNA vaccines with Pfizer Inc. and BioNTech SE in the US,…

Kimberly-Clark, Hims & Hers Health, CNH Industrial

U.S. stock index futures extended losses on Friday after a weaker-than-expected July jobs report elevated concerns about the health of…

GSK may have numbers may have been flattered by order timing, says bank

GSK PLC (LSE:GSK, NYSE:GSK) delivered a strong set of second-quarter results, beating expectations on sales, profits, and earnings per share, and…

ANALYSE-FLASH: UBS belässt GSK auf 'Neutral' - Ziel 1600 Pence

ZÜRICH (dpa-AFX Broker) - Die Schweizer Großbank UBS hat die Einstufung für GSK nach Quartalszahlen…

ROUNDUP: Pharmakonzern GSK überrascht positiv - Aktie profitiert

LONDON (dpa-AFX) - Der britische Arzneimittelhersteller GSK schaut nach einem unerwartet starken zweiten Quartal etwas…

GSK Aktie: Umsatz-Erwartungen in Q2 2025 übertroffen - Neue Medikamente und Impfstoffe stützen Ausblick

Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt die…

GSK confident of hitting top end of 2025 targets after strong second quarter

GSK PLC (LSE:GSK, NYSE:GSK) said on Wednesday it expects to deliver results at the top end of its guidance for the…

Pharmakonzern GSK überrascht im Quartal - steigende Zuversicht

LONDON (dpa-AFX) - Der britische Arzneimittelhersteller GSK schaut nach einem unerwartet starken zweiten Quartal etwas…

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

GSK shares rise on $500m drug deal with China’s Hengrui

Shares in GSK PLC (LSE:GSK, NYSE:GSK) rose in morning trading after the pharmaceutical group announced a $500 million collaboration with Hengrui…

GSK shares rise on $500m drug deal with China’s Hengrui

Shares in GSK PLC (LSE:GSK, NYSE:GSK) rose in morning trading after the pharmaceutical group announced a $500 million collaboration with Hengrui…

GSK to make $500m down payment on Chinese licensing deal worth up to $12bn

GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay $500 million in upfront fees to Chinese drugmaker Hengrui Pharma as part of…

Hengrui Soars as GSK Invests in Chinese Drugmaker’s Pipeline

Jiangsu Hengrui Pharmaceuticals Co. shares rallied to their highest level in four years after GSK Plc agreed to pay $500…

GSK shares analysts get out the red pens after FDA knock-back wipes £3bn from drug makers value

Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell 6% on Thursday, wiping more than £3bn from its market value, after a US…

GSK shares analysts get out the red pens after FDA knock-back wipes £3bn from drug makers value

Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell 6% on Thursday, wiping more than £3bn from its market value, after a US…

GSK shares slide 6% after US panel rejects key cancer drug combination

GSK PLC (LSE:GSK, NYSE:GSK) shares dropped 6% on Friday, erasing over £3 billion from its market value, after a panel of…

AKTIE IM FOKUS: GSK unter Druck - FDA-Ausschuss kritisch zu Krebsmedikament

LONDON (dpa-AFX) - Die Aktien von GSK sind im Vormittagshandel am Freitag unter Druck gekommen.…

GSK gets red light from FDA cancer committee on Blenrep combos

An expert panel advising the US drug regulator has voted against GSK PLCs (LSE:GSK, NYSE:GSK) Blenrep drug combinations for patients with relapsed…

ANALYSE-FLASH: Berenberg belässt GSK auf 'Hold' - Ziel 1600 Pence

HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat die Einstufung für GSK mit einem Kursziel…

ANALYSE-FLASH: JPMorgan belässt GSK auf 'Underweight' - Ziel 1460 Pence

NEW YORK (dpa-AFX Broker) - Die US-Bank JPMorgan hat die Einstufung für GSK mit einem…

AstraZeneca and GSK slide on Trump threats but analysts see positive catalysts ahead

Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) were both down over 1% on Friday, but the shares are worth buying, analysts…

GSK counts on Blenrep rebound to drive £40bn sales goal

GSK PLCs (LSE:GSK, NYSE:GSK) long-term growth ambitions hinge in part on Blenrep, its treatment for multiple myeloma, a type of…

GSK seeks broader European approval for RSV vaccine

GSK PLC (LSE:GSK, NYSE:GSK) has taken a step towards widening access to its respiratory syncytial virus (RSV) vaccine in Europe, with…

ANALYSE-FLASH: Berenberg senkt GSK auf 'Hold' - Ziel 1600 Pence

HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat GSK nach gutem Lauf bei unverändertem Kursziel…

Jemperli (Dostarlimab) Market Report 2025: Epidemiology, Pipeline Analysis, Insights & Forecasts 2019-2024, 2024-2029F, 2034F

The key company operating in the jemperli (dostarlimab) market is GlaxoSmithKline (GSK) Plc. North America was the largest region in…

ANALYSE-FLASH: JPMorgan belässt GSK auf 'Underweight' - Ziel 1460 Pence

NEW YORK (dpa-AFX Broker) - Die US-Bank JPMorgan hat die Einstufung für GSK mit einem…

GSK splashes out $1.2bn up-front for liver treatment still in clinical trials

GSK PLC (LSE:GSK, NYSE:GSK) has struck a deal to acquire a drug to treat and prevent the progression of steatotic liver…

GSK: Disproportionately discounted, but earnings beat shows signs of reappraisal

Shore Capital is sticking with its upbeat view on GSK PLC (LSE:GSK, NYSE:GSK), calling the stock “disproportionately discounted” after first-quarter…

GSK jumps 4% as earnings beat boosts confidence

GSK PLC (LSE:GSK, NYSE:GSK) shares rose 4% on Tuesday, adding £2.6 billion to its market value, after the drugmaker delivered better-than-expected...…

GSK beats earnings forecasts despite weaker vaccine sales

GSK PLC (LSE:GSK, NYSE:GSK) reported earnings ahead of expectations and kept full-year guidance intact, even though sales of vaccines softened. The…

GSK verdient zum Jahresauftakt überraschend viel

LONDON (dpa-AFX) - Der britische Arzneimittelhersteller GSK hat im ersten Quartal sein schwaches Impfgeschäft durch…

GSK update brings US vaccine exposure into spotlight, as sceptic RFK Jr looms

First-quarter results from GSK PLC (LSE:GSK, NYSE:GSK) will focus on commentary around the outlook, including interpretation of US policy changes under...…

GSK DEADLINE ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages GSK plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – GSK

NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

dpa-AFX ProFeed